Clinical Trial

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-06-20; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2026-03-17
Status change: Not Yet Recruiting → Recruiting 2023-07-10
Trial Details
NCT Number NCT05923190
Lead Sponsor Fox Chase Cancer Center
Conditions Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Enrollment 60 participants
Start Date 2023-06-14
Primary Completion 2028-07-01 (estimated)
Study Completion 2029-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-19